Figure 1.

Disease parameters relative to dose 2 of the SARS-CoV-2 vaccine series. (A) The platelet count of patient 1 exhibited a mild decrease after dose 1 and a marked decrease after dose 2. The eltrombopag daily dose was adjusted to compensate for dynamic platelet destruction. (B) In patient 2, the hemolysis marker, LDH, rapidly increased after dose 2. Eculizumab was administered on day 3, with excellent response. (C) In patient 3, factor VIII and vWF activities were initially undetectable, but increased in response to methylprednisolone (MP) and prednisone (pred), Humate-P, and IVIg. aPTT improved concurrently. Red blood cell transfusion and hematocrit are noted.